| 注册
首页|期刊导航|中国中西医结合外科杂志|参芪扶正注射液联合多西他赛对乳腺癌患者细胞免疫功能影响

参芪扶正注射液联合多西他赛对乳腺癌患者细胞免疫功能影响

陆蓉 沈忠卫 曹柳云

中国中西医结合外科杂志2018,Vol.24Issue(2):149-155,7.
中国中西医结合外科杂志2018,Vol.24Issue(2):149-155,7.DOI:10.3969/j.issn.1007-6948.2018.02.005

参芪扶正注射液联合多西他赛对乳腺癌患者细胞免疫功能影响

Effect of Shenqi Fuzheng Injection combined with Docetaxel on Cellular Immune Function in Patients with Terminal Breast Cancer

陆蓉 1沈忠卫 2曹柳云3

作者信息

  • 1. 上海市崇明区东平镇社区卫生服务中心 上海 202178
  • 2. 上海崇明区建设镇社区卫生服务中心 上海 202155
  • 3. 上海市崇明区中兴镇社区卫生服务中心 上海 202163
  • 折叠

摘要

Abstract

Objective To assess the effect of Shenqi Fuzheng Injection combined with docetaxel on cellular immune function in patients with terminal breast cancer. Methods One hundred hospitalized patients with terminal breast cancer were collected and divided into study group (Shenqi Fuzheng Injection with docetaxel routine chemotherapy) and control group (normal saline with routine chemotherapy), 50 cases in each group. All patients were treated with routine chemotherapy, the patients in the study group were treated with Shenqi Fuzheng Injection with docetaxel on the basis of control. The curative effect was assessed, and the T lymphocyte subpopulation and dendritic cell markers were detected at the end of the treatment. Results The rate of complete and partial remission in study was 60 % (30 cases ), which was higher than that of control (34 %, 17 cases, P<0.05). The percents of CD 3+ (66.48 ± 9.76)%, CD 4+ (42.89 ± 8.66)%, and CD 4/CD 8 rate (1.88±0.84)% in post-treatment were higher than that of pre-treatment (59.68±8.54)%, (22.67±5.59)% and (1.06±0.56)% (P<0.05) and control (61.59±8.77)%, (25.16±4.69)% and (1.23±0.71)% (P<0.05), but the percent of CD8+ in study group (22.55±3.79)% was lower than that in pretreatment (29.36±4.62)% and control (28.87±5.19)% (P<0.05). In addition, the percents of CD80, CD83 and CD8 of study group in post-treatment (9.29±2.78)%, (12.48±3.26)% and (48.17±11.21)% were higher than those in pre-treatment (6.76±1.59)%, (8.26±2.15)% and (35.49±8.73)% (P<0.05), but there was no significant difference between pre-treatment and post-treatment in control group. Adverse event of study group was lower than that in control group (28% vs 52%, P<0.05). Conclusion Shenqi Fuzheng Injection combined with docetaxel can improve the immune function in patients with terminal breast cancer, and Shenqi Fuzheng Injection can be used as adjuvant drug for reducing toxicity and enhancing efficacy in the process of chemotherapy of breast cancer.

关键词

乳腺癌/参芪扶正注射液/中医药/化疗

Key words

Breast cancer/Shenqi Fuzheng Injection/traditional Chinese medicine/chemotherapy

分类

医药卫生

引用本文复制引用

陆蓉,沈忠卫,曹柳云..参芪扶正注射液联合多西他赛对乳腺癌患者细胞免疫功能影响[J].中国中西医结合外科杂志,2018,24(2):149-155,7.

中国中西医结合外科杂志

OACSTPCD

1007-6948

访问量0
|
下载量0
段落导航相关论文